[Translation] A randomized, double-blind, multicenter, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of Yushuda tablets in the treatment of mild to moderate depression (dampness and turbidity obstructing the spleen, qi stagnation syndrome)
以治疗 8 周后 HAMD17总分与基线相比的减分值为主要疗效指标,采用随机、双盲、安慰剂平行对照、多中心临床试验设计,评价郁枢达
片用于治疗轻中度抑郁症(湿浊困脾、气机郁滞证)有效性及安全性确证性临床试验。
[Translation] The reduction of HAMD17 total score after 8 weeks of treatment compared with the baseline was used as the primary efficacy indicator. A randomized, double-blind, placebo-controlled, multicenter clinical trial design was used to evaluate the efficacy and safety of Yushuda Tablets in the treatment of mild to moderate depression (dampness and turbidity obstructing the spleen, qi stagnation syndrome).